Research programme: peripherally acting cannabinoid receptor CB1 antagonists - Jenrin Discovery

Drug Profile

Research programme: peripherally acting cannabinoid receptor CB1 antagonists - Jenrin Discovery

Alternative Names: JD-2000 series; JD-2114; JD-5000 series; JD-5006; JD-5037; JD-6000 series

Latest Information Update: 17 Sep 2013

Price : $50

At a glance

  • Originator Jenrin Discovery
  • Class Small molecules
  • Mechanism of Action Cannabinoid 1 receptor inverse agonists; Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Diabetes mellitus; Hyperlipidaemia; Non-alcoholic fatty liver disease; Obesity

Most Recent Events

  • 11 Sep 2013 Pharmacodynamics data from preclinical studies in Diabetes mellitus, Obesity and Non-alcoholic fatty liver disease released by Jenrin Discovery
  • 01 Sep 2013 Preclinical development is ongoing for Hyperlipidaemia in USA
  • 01 Sep 2013 Preclinical trials in Atherosclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top